EP0580860B2
(de)
*
|
1991-04-16 |
2004-12-15 |
Nippon Shinyaku Company, Limited |
Verfahren zur herstellung einer festen dispersion
|
ES2307482T3
(es)
|
1999-02-10 |
2008-12-01 |
Pfizer Products Inc. |
Dispersiones farmaceuticas solidas.
|
DE19930454A1
(de)
*
|
1999-07-02 |
2001-01-04 |
Knoll Ag |
Feste Paroxetin enthaltende Zubereitungen
|
JP5767429B2
(ja)
*
|
1999-11-12 |
2015-08-19 |
アッヴィ・インコーポレイテッド |
固体分散剤中の結晶化阻害剤
|
US7364752B1
(en)
|
1999-11-12 |
2008-04-29 |
Abbott Laboratories |
Solid dispersion pharamaceutical formulations
|
EP2415462A1
(de)
*
|
1999-12-23 |
2012-02-08 |
Mayne Pharma International Pty Ltd. |
Verbesserte pharmazeutische Zusammensetzungen für schwerlösliche Arzneistoffe
|
JP2003518485A
(ja)
|
1999-12-23 |
2003-06-10 |
ファイザー・プロダクツ・インク |
向上された薬物濃度を与える医薬組成物
|
UY26615A1
(es)
|
2000-03-16 |
2001-10-25 |
Pfizer Prod Inc |
Inhibidor de la glucogeno fosforilasa.
|
DE10026698A1
(de)
|
2000-05-30 |
2001-12-06 |
Basf Ag |
Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
|
HU229550B1
(en)
|
2000-06-27 |
2014-01-28 |
Hoffmann La Roche |
Method for preparing compositions
|
US7115279B2
(en)
*
|
2000-08-03 |
2006-10-03 |
Curatolo William J |
Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
|
US7198795B2
(en)
*
|
2000-09-21 |
2007-04-03 |
Elan Pharma International Ltd. |
In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
|
EE200300476A
(et)
*
|
2001-04-02 |
2003-12-15 |
Astrazeneca Ab |
4-tsüanotrifluoro-3-(4-fluorofenüülsulfonüül)-2-hüdroksü-2-metüülpropiono-m-toluidii di ja PVP-d sisaldav tahke farmatseutiline kompositsioon
|
EP1269994A3
(de)
|
2001-06-22 |
2003-02-12 |
Pfizer Products Inc. |
Pharmazeutische Zusammensetzungen die ein Arzneimittel und die Konzentration verbesserende Polymere enthalten
|
AU2002304387A1
(en)
*
|
2001-06-22 |
2003-01-08 |
Pfizer Products Inc. |
Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer
|
MXPA03011933A
(es)
|
2001-06-22 |
2004-03-26 |
Pfizer Prod Inc |
Composiciones farmaceuticas de farmacos y polimeros acidos neutralizados.
|
EP1401399A2
(de)
*
|
2001-06-22 |
2004-03-31 |
Pfizer Products Inc. |
Pharmzeutische zubereitungen enthaltend anlagerungsprodukte aus polymer und wirkstoff
|
JP2004534812A
(ja)
*
|
2001-06-22 |
2004-11-18 |
ファイザー・プロダクツ・インク |
薬物および中性ポリマーの分散物の医薬組成物
|
SE0103838D0
(sv)
*
|
2001-11-16 |
2001-11-16 |
Astrazeneca Ab |
Pharmaceutical formulation & product
|
CA2474838C
(en)
|
2002-02-01 |
2009-01-06 |
Pfizer Products Inc. |
Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
|
JP2005523260A
(ja)
|
2002-02-01 |
2005-08-04 |
ファイザー・プロダクツ・インク |
圧力ノズルを用いた均質噴霧乾燥固体非晶質薬剤分散体の製造方法
|
EP1920766B1
(de)
*
|
2002-02-01 |
2017-08-23 |
Bend Research, Inc |
Pharmazeutische Zusammensetzungen amorpher Dispersionen von Wirkstoffen und lipophiler mikrophasenbildender Materialien
|
AR038375A1
(es)
*
|
2002-02-01 |
2005-01-12 |
Pfizer Prod Inc |
Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
|
MXPA04007433A
(es)
|
2002-02-01 |
2004-10-11 |
Pfizer Prod Inc |
Procedimiento para preparar dispersiones solidas amorfas homogeneas de farmaco secadas por pulverizacion utilizando un dispositivo de secado por pulverizacion modificado.
|
DE60329188D1
(de)
|
2002-08-12 |
2009-10-22 |
Bend Res Inc |
Arzneizubereitungen bestehend aus arzneimitteln in halb-geordneter form und polymeren
|
KR100556503B1
(ko)
*
|
2002-11-26 |
2006-03-03 |
엘지전자 주식회사 |
건조기의 건조 시간제어 방법
|
US7423004B2
(en)
|
2003-01-31 |
2008-09-09 |
Smithkline Beecham Corporation |
Solid dispersion compositions
|
US7790197B2
(en)
|
2003-06-09 |
2010-09-07 |
Warner-Lambert Company Llc |
Pharmaceutical compositions of atorvastatin
|
US7655692B2
(en)
|
2003-06-12 |
2010-02-02 |
Pfizer Inc. |
Process for forming amorphous atorvastatin
|
CL2004001884A1
(es)
|
2003-08-04 |
2005-06-03 |
Pfizer Prod Inc |
Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
|
ATE540671T1
(de)
|
2003-08-04 |
2012-01-15 |
Bend Res Inc |
Pharmazeutische zusammensetzungen von adsorbaten von amorphen arzneimitteln und lipophilen mikrophasen-bildenden materialien
|
US20050048112A1
(en)
|
2003-08-28 |
2005-03-03 |
Jorg Breitenbach |
Solid pharmaceutical dosage form
|
US8025899B2
(en)
|
2003-08-28 |
2011-09-27 |
Abbott Laboratories |
Solid pharmaceutical dosage form
|
US8377952B2
(en)
*
|
2003-08-28 |
2013-02-19 |
Abbott Laboratories |
Solid pharmaceutical dosage formulation
|
CN1905860A
(zh)
*
|
2003-11-21 |
2007-01-31 |
先灵公司 |
磷酸二酯酶v抑制剂制剂
|
JP2007517015A
(ja)
*
|
2003-12-31 |
2007-06-28 |
ファイザー・プロダクツ・インク |
低溶解性薬物、ポロキサマーおよび安定化ポリマーの安定化された医薬用固体組成物
|
MXPA06013891A
(es)
|
2004-05-28 |
2007-01-26 |
Pfizer Prod Inc |
Composiciones farmaceuticas con comportamiento potenciado.
|
GB0428152D0
(en)
*
|
2004-12-22 |
2005-01-26 |
Novartis Ag |
Organic compounds
|
NZ555693A
(en)
*
|
2004-12-27 |
2010-10-29 |
Eisai R&D Man Co Ltd |
Matrix type sustained-release preparation containing donepezil
|
EP1844078B1
(de)
*
|
2005-02-03 |
2016-09-28 |
Bend Research, Inc |
Pharmazeutische zusammensetzungen mit erhöhter leistung
|
GB0502790D0
(en)
*
|
2005-02-10 |
2005-03-16 |
Univ London Pharmacy |
Solid dispersion of hydrophobic bioactive
|
WO2007014393A2
(en)
*
|
2005-07-28 |
2007-02-01 |
Isp Investments Inc. |
Amorphous efavirenz and the production thereof
|
BRPI0615609A2
(pt)
*
|
2005-08-29 |
2011-05-24 |
Sanofi Aventis Us Llc |
dispersões sólidas amorfas
|
EA017290B1
(ru)
|
2005-11-28 |
2012-11-30 |
Домейн Раша Инвестментс Лимитед |
Композиции на основе ганаксолона
|
WO2008054508A2
(en)
*
|
2006-04-13 |
2008-05-08 |
Alza Corporation |
Stable nanosized amorphous drug
|
WO2007141308A1
(en)
*
|
2006-06-06 |
2007-12-13 |
Tibotec Pharmaceuticals Ltd. |
Process for preparing spray dried formulations of tmc125
|
WO2008002485A2
(en)
*
|
2006-06-23 |
2008-01-03 |
Alza Corporation |
Increased amorphous stability of poorly water soluble drugs by nanosizing
|
GB0613925D0
(en)
*
|
2006-07-13 |
2006-08-23 |
Unilever Plc |
Improvements relating to nanodispersions
|
EP2081435B1
(de)
|
2006-09-22 |
2016-05-04 |
Pharmacyclics LLC |
Hämmer der bruton-tyrosinkinase
|
US20080085315A1
(en)
*
|
2006-10-10 |
2008-04-10 |
John Alfred Doney |
Amorphous ezetimibe and the production thereof
|
US20080107725A1
(en)
*
|
2006-10-13 |
2008-05-08 |
Albano Antonio A |
Pharmaceutical Solid Dosage Forms Comprising Amorphous Compounds Micro-Embedded in Ionic Water-Insoluble Polymers
|
DE602007008470D1
(en)
*
|
2006-10-17 |
2010-09-23 |
Bend Res Inc |
Off
|
CA2667065A1
(en)
*
|
2006-11-13 |
2008-05-22 |
Basf Se |
Use of block copolymers based on vinyllactams and vinyl acetate as solubilizers
|
US10357462B2
(en)
|
2006-11-30 |
2019-07-23 |
Ben Research, Inc. |
Multiparticulates of spray-coated drug and polymer on a meltable core
|
US11116728B2
(en)
|
2006-11-30 |
2021-09-14 |
Bend Research, Inc. |
Multiparticulates of spray-coated drug and polymer on a meltable core
|
PE20081506A1
(es)
*
|
2006-12-12 |
2008-12-09 |
Infinity Discovery Inc |
Formulaciones de ansamicina
|
US20080152717A1
(en)
*
|
2006-12-14 |
2008-06-26 |
Isp Investments, Inc. |
Amorphous valsartan and the production thereof
|
WO2008080037A2
(en)
*
|
2006-12-21 |
2008-07-03 |
Isp Investments Inc. |
Carotenoids of enhanced bioavailability
|
JP5508859B2
(ja)
|
2007-01-26 |
2014-06-04 |
アイエスピー インヴェストメンツ インコーポレイテッド |
噴霧乾燥製品を製造するための調剤処理方法
|
EP2305263B1
(de)
*
|
2007-06-07 |
2012-09-19 |
Novartis AG |
Stabilisierte amorphe Formen von Imatinib Mesylat
|
CA2692738A1
(en)
*
|
2007-07-12 |
2009-01-15 |
Dr. Reddy's Laboratories, Ltd. |
O-desmethylvenlafaxine
|
CA2699157A1
(en)
|
2007-09-10 |
2009-03-19 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
EP2105130A1
(de)
|
2008-03-25 |
2009-09-30 |
Ratiopharm GmbH |
Pharmazeutische Formulierung und Verfahren zu deren Herstellung
|
EP2133068A1
(de)
|
2008-06-13 |
2009-12-16 |
Ratiopharm GmbH |
Verfahren zur Auswahl eines geeigneten Hilfsstoffs für die Herstellung von festen Dispersionen für pharmazeutische Formulierungen
|
MX2011002149A
(es)
|
2008-08-27 |
2011-04-05 |
Calcimedica Inc |
Compuestos que modulan el calcio intracelular.
|
GB0815852D0
(en)
*
|
2008-09-01 |
2008-10-08 |
Unilever Plc |
Improvements relating to pharmaceutical compositions
|
JP5757681B2
(ja)
|
2009-08-12 |
2015-07-29 |
富士フイルム株式会社 |
セルロース誘導体、樹脂組成物、成形体及びその製造方法並びに電気電子機器用筐体
|
US7741330B1
(en)
|
2009-10-12 |
2010-06-22 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
|
EP2366378A1
(de)
|
2010-03-01 |
2011-09-21 |
Dexcel Pharma Technologies Ltd. |
Donepezilformulierungen mit verzögerter Freisetzung
|
EP2558866B1
(de)
|
2010-04-15 |
2016-08-17 |
Tracon Pharmaceuticals, Inc. |
Potenzierung einer antikrebs-wirkung durch eine kombinationstherapie mit ber-pfad-hemmern
|
WO2011139489A2
(en)
|
2010-04-27 |
2011-11-10 |
Calcimedica Inc. |
Compounds that modulate intracellular calcium
|
AU2011248579A1
(en)
|
2010-04-27 |
2012-11-29 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
CN103153306A
(zh)
*
|
2010-05-31 |
2013-06-12 |
安斯泰来制药有限公司 |
三唑化合物的固体分散体
|
WO2011163090A1
(en)
|
2010-06-23 |
2011-12-29 |
Metabolex, Inc. |
Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
|
US9079891B2
(en)
|
2010-08-27 |
2015-07-14 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
EP2572731A1
(de)
*
|
2011-09-26 |
2013-03-27 |
Abbott GmbH & Co. KG |
Formulierungen basierend auf Festdispergierungen
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
WO2013169523A1
(en)
*
|
2012-05-07 |
2013-11-14 |
Bpsi Holdings, Llc. |
Solubility enhanced compositions
|
NZ702548A
(en)
|
2012-06-04 |
2015-11-27 |
Pharmacyclics Llc |
Crystalline forms of a bruton’s tyrosine kinase inhibitor
|
EP2863911A4
(de)
|
2012-06-21 |
2016-07-13 |
Mayne Pharma Int Pty Ltd |
Itraconazolzusammensetzungen sowie dosierungsformen und verfahren zur verwendung davon
|
US9512116B2
(en)
|
2012-10-12 |
2016-12-06 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
NZ625087A
(en)
|
2013-01-31 |
2017-05-26 |
Gilead Pharmasset Llc |
Combination formulation of two antiviral compounds
|
EP2832723B1
(de)
*
|
2013-07-29 |
2017-02-15 |
Zentiva, a.s. |
Stabilisierte amorphe Formen von Saxagliptin
|
ES2900570T3
(es)
|
2013-08-27 |
2022-03-17 |
Gilead Pharmasset Llc |
Formulación de combinación de dos compuestos antivirales
|
WO2015054283A1
(en)
|
2013-10-08 |
2015-04-16 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
WO2015071841A1
(en)
|
2013-11-12 |
2015-05-21 |
Druggability Technologies Holdings Limited |
Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
|
WO2015084998A1
(en)
|
2013-12-05 |
2015-06-11 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
US20150224078A1
(en)
|
2014-02-10 |
2015-08-13 |
Patara Pharma, LLC |
Methods for the Treatment of Lung Diseases with Mast Cell Stabilizers
|
SI3104853T1
(sl)
|
2014-02-10 |
2020-03-31 |
Respivant Sciences Gmbh |
Zdravljenje s stabilizatorji mastocitov za sistemske motnje
|
WO2015164213A1
(en)
|
2014-04-23 |
2015-10-29 |
The Research Foundation For The State University Of New York |
A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith
|
US9955318B1
(en)
|
2014-06-05 |
2018-04-24 |
Steelcase Inc. |
Space guidance and management system and method
|
JP2017523206A
(ja)
*
|
2014-08-07 |
2017-08-17 |
ファーマサイクリックス エルエルシー |
ブルトン型チロシンキナーゼ阻害剤の新規製剤
|
US9839644B2
(en)
|
2014-09-09 |
2017-12-12 |
ARKAY Therapeutics, LLC |
Formulations and methods for treatment of metabolic syndrome
|
US9359316B1
(en)
|
2014-11-25 |
2016-06-07 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic TRPV1 agonists
|
US10227333B2
(en)
|
2015-02-11 |
2019-03-12 |
Curtana Pharmaceuticals, Inc. |
Inhibition of OLIG2 activity
|
JP2018510138A
(ja)
|
2015-02-27 |
2018-04-12 |
カーテナ ファーマシューティカルズ,インク. |
Olig2活性の阻害
|
BR122023020985A2
(pt)
|
2015-03-03 |
2023-12-26 |
Pharmacyclics Llc |
Formulação de comprimido sólido de um inibidor de tirosina quinase de bruton
|
WO2017027402A1
(en)
|
2015-08-07 |
2017-02-16 |
Patara Pharma, LLC |
Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
|
US10238625B2
(en)
|
2015-08-07 |
2019-03-26 |
Respivant Sciences Gmbh |
Methods for the treatment of mast cell related disorders with mast cell stabilizers
|
AU2016364976B2
(en)
*
|
2015-11-30 |
2022-08-25 |
Cyclerion Therapeutics, Inc. |
Solid dispersions comprising a sGC stimulator
|
WO2017147146A1
(en)
|
2016-02-23 |
2017-08-31 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic trpv1 agonists
|
ES2910787T3
(es)
|
2016-05-12 |
2022-05-13 |
Univ Michigan Regents |
Inhibidores de ASH1L y métodos de tratamiento con los mismos
|
US10821105B2
(en)
|
2016-05-25 |
2020-11-03 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic TRPV1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
|
WO2017205766A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
WO2017205769A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
WO2017205762A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
JP7028860B2
(ja)
|
2016-08-26 |
2022-03-02 |
カーテナ ファーマシューティカルズ,インク. |
Olig2活性の阻害
|
CA3035528A1
(en)
|
2016-08-31 |
2018-03-08 |
Respivant Sciences Gmbh |
Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
|
EP3522983A4
(de)
|
2016-10-07 |
2020-06-03 |
Respivant Sciences GmbH |
Cromolynzusammensetzung zur behandlung von lungenfibrose
|
JP7013454B2
(ja)
*
|
2016-10-12 |
2022-02-15 |
イントラ-セルラー・セラピーズ・インコーポレイテッド |
アモルファス固体分散体
|
WO2019094434A1
(en)
|
2017-11-07 |
2019-05-16 |
The Regents Of The University Of Michigan |
Therapeutic combination for treatment of cerebellar ataxia
|
WO2019094773A1
(en)
|
2017-11-10 |
2019-05-16 |
The Regents Of The University Of Michigan |
Ash1l inhibitors and methods of treatment therewith
|
CN112040947A
(zh)
|
2017-12-07 |
2020-12-04 |
密歇根大学董事会 |
Nsd家族抑制剂及用其进行治疗的方法
|
JP7244536B2
(ja)
|
2018-04-06 |
2023-03-22 |
キャプシュゲル・ベルジウム・エヌ・ヴィ |
メタクリル酸メチル-メタクリル酸コポリマーからなる低アスペクト比の粒子のための噴霧乾燥方法
|
CN110551224B
(zh)
*
|
2018-05-30 |
2022-04-22 |
华南理工大学 |
一种超耐折纳米纤维素薄膜及其制备方法
|
US11319302B2
(en)
|
2018-06-07 |
2022-05-03 |
The Regents Of The University Of Michigan |
PRC1 inhibitors and methods of treatment therewith
|
WO2020023794A1
(en)
|
2018-07-27 |
2020-01-30 |
Concentric Analgesics, Inc. |
Pegylated prodrugs of phenolic trpv1 agonists
|
US20200069742A1
(en)
|
2018-08-29 |
2020-03-05 |
Myos Rens Technology Inc. |
Methods for alleviating, inhibiting or reversing muscle disuse atrophy in mammals
|
US20200108102A1
(en)
|
2018-10-03 |
2020-04-09 |
Myos Rens Technology Inc. |
Spray dried follistatin product
|
WO2020096660A1
(en)
|
2018-11-06 |
2020-05-14 |
Myos Rens Technology, Inc. |
Methods and compositions for improving skeletal muscle protein fractional synthetic rate
|
MX2021007925A
(es)
|
2018-12-31 |
2021-10-26 |
Biomea Fusion Llc |
Inhibidores irreversibles de la interaccion menina-mll.
|
US11833186B2
(en)
|
2019-02-01 |
2023-12-05 |
Myos Corp. |
Methods and compositions for improving quality of life and increasing activity in aging and chronically ill mammals
|
CN109730967B
(zh)
*
|
2019-02-19 |
2021-08-03 |
广东工业大学 |
一种硝苯地平固体分散体及其制备方法
|
WO2020190890A1
(en)
|
2019-03-15 |
2020-09-24 |
Unicycive Therapeutics Inc. |
Nicorandil derivatives
|
EP4093379A1
(de)
|
2020-01-24 |
2022-11-30 |
Nanocopoeia LLC |
Amorphe feste dispersionen von dasatinib und deren verwendungen
|
JP2023513045A
(ja)
|
2020-01-31 |
2023-03-30 |
ナノコピーア リミテッド ライアビリティ カンパニー |
非晶質ニロチニブ微粒子及びその使用
|
EP4142715A1
(de)
*
|
2020-04-26 |
2023-03-08 |
Apollomics Inc. |
Neue pharmazeutische formulierung für c-met-hemmer
|
WO2021222739A1
(en)
|
2020-04-30 |
2021-11-04 |
Nanocopoeia, Llc |
Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
|
CN116113406A
(zh)
|
2020-07-10 |
2023-05-12 |
密歇根大学董事会 |
Gas41抑制剂及其使用方法
|
CA3202151A1
(en)
|
2020-12-16 |
2022-06-23 |
Biomea Fusion, Inc. |
Fused pyrimidine compounds as inhibitors of menin-mll interaction
|
CN112791056A
(zh)
*
|
2021-01-22 |
2021-05-14 |
河北农业大学 |
一种氟苯尼考固体分散体及其制备方法
|
WO2023018825A1
(en)
|
2021-08-11 |
2023-02-16 |
Biomea Fusion, Inc. |
Covalent inhibitors of menin-mll interaction for diabetes mellitus
|
WO2023027966A1
(en)
|
2021-08-24 |
2023-03-02 |
Biomea Fusion, Inc. |
Pyrazine compounds as irreversible inhibitors of flt3
|
WO2023039240A1
(en)
|
2021-09-13 |
2023-03-16 |
Biomea Fusion, Inc. |
IRREVERSIBLE INHIBITORS OF KRas
|
WO2023086341A1
(en)
|
2021-11-09 |
2023-05-19 |
Biomea Fusion, Inc. |
Inhibitors of kras
|
US11945785B2
(en)
|
2021-12-30 |
2024-04-02 |
Biomea Fusion, Inc. |
Pyrazine compounds as inhibitors of FLT3
|
CN114917199A
(zh)
*
|
2022-05-24 |
2022-08-19 |
长治医学院 |
一种白藜芦醇亲水凝胶骨架缓释片及其制备方法
|
WO2023235618A1
(en)
|
2022-06-03 |
2023-12-07 |
Biomea Fusion, Inc. |
Fused pyrimidine compounds as inhibitors of menin
|